The partners aim to enable automatic processing from a wide range of sample types, such as nucleic acids extracted from sorted cells, fine needle aspirates, formalin-fixed paraffin embedded tissue, and other limited or degraded clinical samples.
The researchers said the method increases the number of samples that can be sequenced at once, reduces the cost per sample, and will be particularly amenable for viral sequencing projects.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
